Infectious risk of plasma donations: relationship to safety of intravenous immune globulins
暂无分享,去创建一个
[1] P. Yap,et al. The viral safety of intravenous immune globulin , 1996, Clinical and experimental immunology.
[2] M. Björkholm,et al. Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward , 1995, The Lancet.
[3] G. Satten,et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors , 1995, Transfusion.
[4] G. Satten,et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody , 1994, Transfusion.
[5] P. Snoy,et al. The effect on the safety of intravenous immunoglobulin of testing plasma for antibody to hepatitis C , 1994, Transfusion.
[6] Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. , 1994, MMWR. Morbidity and mortality weekly report.
[7] J. McCullough. The nation's changing blood supply system. , 1993, JAMA.
[8] M. A. Lamb,et al. Viral safety of clotting factor concentrates. , 1993, Seminars in thrombosis and hemostasis.
[9] H. Suomela. Inactivation of viruses in blood and plasma products. , 1993, Transfusion medicine reviews.
[10] M. Busch,et al. Increased detection of hepatitis C virus (HCV)‐infected blood donors by a multiple‐antigen HCV enzyme immunoassay , 1992, Transfusion.
[11] S. Yei,et al. Partitioning of hepatitis C virus during Cohn‐Oncley fractionation of plasma , 1992, Transfusion.
[12] A. Muñoz,et al. Transmission of Retroviruses from Seronegative Donors by Transfusion during Cardiac Surgery , 1992, Annals of Internal Medicine.
[13] R. Dodd. The risk of transfusion-transmitted infection. , 1992, The New England journal of medicine.
[14] J. Sninsky,et al. Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. , 1991, The New England journal of medicine.
[15] G. Macchi,et al. Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. , 1991, Hormone research.
[16] S. Kleinman,et al. Risk of human immunodeficiency virus (HIV) transmission by anti‐HIV negative blood , 1988, Transfusion.
[17] P. Holland. Why a new standard to prevent Creutzfeldt‐Jakob disease , 1988, Transfusion.
[18] J. Ward,et al. Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. , 1988, The New England journal of medicine.
[19] D. Kingsbury,et al. Chemical disinfection of Creutzfeldt-Jakob disease virus. , 1982, The New England journal of medicine.